Acute Care Syndromic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others), By Target (Bacteria, Viruses, Fungi, Parasites), By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others), By End User (Hospitals, Clinical and Diagnostic
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAcute Care Syndromic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others), By Target (Bacteria, Viruses, Fungi, Parasites), By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others), By End User (Hospitals, Clinical and Diagnostic
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 2.89 billion |
| CAGR (2023-2028) | 5.56% |
| Fastest Growing Segment | Respiratory Disease Segment |
| Largest Market | Asia Pacific |
Market Overview
Global Acute Care Syndromic Testing Market has valued at USD 2.89 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.56% through 2028. Acute Care Syndromic Testing Markets are diagnostic approach used in healthcare settings, particularly in emergency departments and acute care facilities, to rapidly identify and diagnose the cause of acute symptoms or conditions in patients. This approach involves the simultaneous testing of multiple pathogens (such as viruses, bacteria, and other microorganisms) that could be responsible for a patient's symptoms. The goal is to quickly narrow down the potential causes and guide appropriate treatment decisions. Acute care syndromic testing is especially important in situations where patients present with symptoms that could be attributed to various infectious agents. This testing strategy allows healthcare providers to make timely and informed decisions regarding patient care, isolation measures, and treatment options. It can be particularly valuable during disease outbreaks or pandemics, as it helps healthcare systems efficiently manage and respond to a large number of patients with similar symptoms. However, The specific types of tests used in acute care syndromic testing may include molecular assays (like polymerase chain reaction or PCR tests), rapid antigen tests, serological tests (looking for antibodies), and other diagnostic methods. The choice of tests depends on the suspected pathogens and the clinical context.
Key Market Drivers
Rise in Infectious Disease Outbreaks Propels The Market Growth
Influenza is the most common infectious disease in the world, but some diseases are more prevalent than others. In the United States alone, about 1 in every 5 people gets the flu every year, but only about 300 people get prion disease each year.
The collective impact of these factors creates a strong demand for acute care syndromic testing solutions during infectious disease outbreaks. This demand, in turn, drives investment in research and development, technological advancements, and adoption of syndromic testing platforms, contributing to the growth of the global acute care syndromic testing market.
Increasing Demand for Timely Diagnostics Drives the Market Growth
The increasing demand for timely diagnostics plays a crucial role in driving the growth of the global acute care syndromic testing market. Timely diagnostics are essential for a range of medical conditions, especially in acute care settings, where rapid and accurate diagnosis can significantly impact patient outcomes. Here's how the demand for timely diagnostics contributes to the growth of the acute care syndromic testing market. In acute care settings, such as emergency departments, rapid and accurate diagnosis is essential for making urgent treatment decisions. Acute care syndromic testing provides a comprehensive analysis of potential pathogens, enabling healthcare providers to quickly identify the cause of symptoms and initiate appropriate treatment protocols. Acute care syndromic testing platforms are designed to provide quick results, often within a matter of hours. This rapid turnaround time is crucial for situations where immediate diagnosis is necessary to prevent disease progression or complications. Timely diagnostics help healthcare providers efficiently manage patients' conditions. Acute care syndromic testing aids in patient triage, isolation, and targeted interventions, allowing for optimal resource allocation and care planning. Traditional diagnostic methods can sometimes lead to delays due to laboratory processing times and sample transportation. Acute care syndromic testing reduces the risk of delays and backlogs, ensuring that patients receive timely diagnoses and treatments. Rapid diagnosis through acute care syndromic testing can lead to improved patient outcomes. Early initiation of appropriate therapies can reduce the severity of illness, lower mortality rates, and decrease the risk of complications.
Increased Adoption Of Point-Of-Care Testing Drives the Market Growth
The increased adoption of point-of-care (POC) testing significantly drives the growth of the global acute care syndromic testing market. Point-of-care testing refers to diagnostic testing that is performed at or near the patient's location, such as a hospital bedside, clinic, or other healthcare settings. Point-of-care testing provides immediate results, enabling healthcare providers to quickly diagnose patients' conditions and make timely treatment decisions. In acute care settings, where time is critical, rapid diagnosis through POC testing can lead to faster initiation of appropriate therapies. Traditional laboratory testing often involves sending samples to centralized labs, leading to longer turnaround times for results. POC testing eliminates the need for sample transportation and processing delays, ensuring that patients receive timely diagnoses. POC testing streamlines patient management by allowing healthcare providers to assess patients' conditions and determine appropriate treatments without waiting for lab results. This efficiency is especially valuable in acute care scenarios. With POC testing, treatment can be initiated immediately, leading to better patient outcomes. In cases of infectious diseases, early treatment can reduce the severity of illness and prevent complications. POC testing facilitates comprehensive patient care at the bedside, reducing the need for patients to be transported within the facility for testing. This is particularly important for critically ill patients who may have limited mobility. POC testing helps optimize the use of healthcare resources by reducing the need for additional tests, consultations, and procedures. This can lead to cost savings and improved healthcare efficiency. In emergency situations, POC testing provides crucial diagnostic information quickly, enabling healthcare providers to make informed decisions and prioritize patient care.
Download Free Sample Report
Key Market Challenges
Competition from other diagnostic tests
Syndromic testing competes with other diagnostic tests, such as molecular diagnostics and serological diagnostics. These tests may be more accurate and can provide more information about the underlying cause of the syndrome. molecular diagnostics can identify the specific pathogen causing the syndrome, while serological diagnostics can detect the presence of antibodies to the pathogen. This information can be helpful in making a diagnosis and determining the best course of treatment. Healthcare providers may be more accustomed to using traditional diagnostic methods that they are already familiar with, which can lead to a resistance to adopting newer syndromic testing approaches. Diagnostic methods that have a long history of use and established reliability may be favored by healthcare professionals, making it difficult for syndromic testing to gain traction.
Quality control and standardization
Quality control and standardization are significant challenges in the global acute care syndromic testing market. Ensuring consistent and accurate results across different syndromic testing platforms and assays is essential for the reliability and reproducibility of diagnostic outcomes. Syndromic testing platforms may use different technologies, chemistries, and reagents, leading to variability in assay performance. Differences in sensitivity, specificity, and limit of detection can impact the accuracy and reliability of test results. Syndromic testing may be performed in various laboratory settings, including clinical laboratories, hospitals, and point-of-care facilities. Inter-laboratory variability in testing procedures, equipment, and personnel expertise can affect result consistency. Syndromic testing assays targeting multiple pathogens simultaneously need to minimize cross-reactivity or interference between different targets. Cross-reactivity can lead to false-positive or false-negative results.
Integration with healthcare systems
Integration with healthcare systems poses a significant challenge to the global acute care syndromic testing market. The seamless integration of syndromic testing technologies into existing healthcare systems and workflows is essential for maximizing their benefits and widespread adoption. Syndromic testing platforms need to be compatible with existing healthcare information systems, electronic health records (EHRs), and laboratory information management systems (LIMS). Ensuring smooth data exchange and interoperability can be technically demanding. Syndromic testing generates a substantial amount of data that needs to be managed, stored securely, and accessed by relevant healthcare professionals. Establishing robust data management and connectivity solutions is crucial. Developing user-friendly interfaces that allow healthcare providers to easily access and interpret syndromic testing results within their existing workflow can be complex. User interface design needs to consider usability and efficiency. Healthcare personnel, including clinicians, laboratory technicians, and IT staff, require training to effectively use and integrate syndromic testing technologies. Training programs need to be comprehensive and ongoing. Integrating new technologies often requires changes to established clinical and laboratory workflows. Overcoming resistance to change and ensuring a smooth transition are essential for successful integration.
Key Market Trends
Rise of Point-of-Care-Testing (POCT)
The rise of Point-of-Care Testing (POCT) is a significant trend in the global Acute Care Syndromic Testing Market. Point-of-Care Testing refers to diagnostic testing performed at or near the patient's location, providing rapid results that can guide immediate clinical decision-making.
Segmental Insights
Disease Type
In 2022, the Acute Care Syndromic Testing Market was dominated by the Respiratory Diseases Segment and is predicted to continue expanding over the coming years.
Target Insights
In 2022, the Acute Care Syndromic Testing Markets market was dominated by Bacteria Segment and is predicted to continue expanding over the coming years.
Sample Insight
In 2022, the Acute Care Syndromic Testing Markets market was dominated by Swabs Segment and is predicted to continue expanding over the coming years.
End-User Insight
In 2022, the Acute Care Syndromic Testing Markets market was dominated by Hospital Segment and is predicted to continue expanding over the coming years.
Download Free Sample Report
Regional Insights
The North America region has established itself as the leader in the Global Acute Care Syndromic Testing Markets Market.
Recent Developments
- In May 2023, Hologic Inc., announced that it has been granted 510 (k) clearance by the United States FDA for the development and commercialization of Panther Fusion®, the first molecular diagnostic test for the detection of the four most common respiratory virusesSevere Acute Respiratory Syndrome CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV).
- In April 2023, CLIMADE is a consortium of over 100 scientists from academia and public health organizations around the world who work to reduce the risk of future disease epidemics. Abbott Laboratories has partnered with CLIMADE to leverage diagnostic testing and advanced data science technologies.
- In April 2023, QIAGEN, the world’s leading diagnostics company, today announced the commercial launch of its Japanese-based syndromic testing system, QIAstat-Ds, which is capable of detecting over 20 respiratory pathogens from a single sample, including the highly transmissible coronavirus (SARS)-CoV-2.
Key Market Players
·
·
·
·
·
·
·
·
·
·
·
| By Disease Type | By Target | By Region | By Sample Type | By End User |
| • Respiratory Disease • Gastrointestinal Diseases • Genitourinary Diseases • Tropical Disease • Others | • Bacteria • Viruses • Fungi • Parasites | • Asia Pacific • North America • Europe • Middle East & Africa • South America | • Blood • Urine • Biofluids • Stool • Swabs • Others | • Hospitals • Clinical & Diagnostics Laboratories • Research & Academic Institutions • Others |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy